Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer .
Filed returns
21
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Pfizer | EU Affairs | Ireland’s priorities for the 2026 Presidency of the Council of the European Union, including issues related to life sciences competitiveness (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | EU Affairs | Ireland’s priorities for the 2026 Presidency of the Council of the European Union, including issues related to life sciences competitiveness, pharmaceutical manufacturing, and EU-level health emergency preparedness (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2025 | Pfizer | EU Affairs | Ireland priorities for the Presidency of the Council of the European Union (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 7 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | EU Affairs | PFAS restrictions (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 6 | On lobbying.ie |
| May–Aug 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 14 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 9 | On lobbying.ie |
| Sep–Dec 2023 | Pfizer | EU Affairs | Urban Wastewater Treatment Directive (UWWTD) (Legislation) | 1 | On lobbying.ie |
| May–Aug 2023 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 5 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | EU Affairs | Potential EU proposals to restrict use of titanium dioxide and PFAS in medicines (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | EU Affairs | EU Pharmaceutical Legislation (Legislation) | 3 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | EU Affairs | EC HERA contract in relation to Pfizer COVID-19 vaccine (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | EU Affairs | European System of Accounts (EU Accounting Rules) (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | EU Affairs | EC HERA contract in relation to Pfizer COVID-19 vaccine (Matters involving public funds) | 5 | On lobbying.ie |
| May–Aug 2021 | Pfizer | EU Affairs | Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | EU Affairs | Highlight Pfizer concerns re proposed EU vaccine export restrictions and how this could impact Pfizer's ability to manufacture the COVID 19 vaccine and provide supply globally (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2019 | Pfizer | EU Affairs | The EU Commission is introducing legislation for an SPC (Supplementary Protection Certificate) ‘export exemption’; this would allow companies to manufacture products that have an SPC within the EU for export outside the… (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2018 | Pfizer | EU Affairs | The EU Commission is introducing legislation for an SPC (Supplementary Protection Certificate) ‘export exemption’; this would allow companies to manufacture products that have an SPC within the EU for export outside the… (Legislation) | 2 | On lobbying.ie |
| Sep–Dec 2015 | Pfizer | EU Affairs | ‘On the Fight Against Breast Cancer in the European Union’ (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2015 | Pfizer | EU Affairs | EU Regulation REACH - Registration, Evaluation, Authorisation and Restriction of Chemicals (Legislation) | 2 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| EU Affairs | 21 | 100.0% |